AstraZeneca

AstraZeneca is one of the world’s largest pharmaceutical companies, based in the United Kingdom and dedicated to researching, developing and marketing prescription medicines. It has a strong presence in oncology, cardiovascular, metabolic and kidney diseases, respiratory diseases and immunology, as well as medicines for rare diseases. Its business depends heavily on the quality of its new-drug pipeline and the success of clinical trials.

AZN attracted attention through an unusually large insider signal: Pascal Soriot invested more than £7 million and chairman Michel Demaré bought at the same time, after the market had already received negative clinical news.

The company remained highly profitable, with double-digit EPS growth and a forward P/E that was much more reasonable than the trailing multiple suggested. Pharmaceutical quality, the pipeline, forward valuation and the size of the CEO's purchase supported a score of 9.2.

Pascal Soriot bought 60,000 shares at £121.02, approximately £7.26 million.

Michel Demaré bought 2,500 shares at £121.21, approximately £303,000.

The combined amount was approximately £7.56 million. These purchases used the London share in GBP; the site's Day 0 reference uses the NYSE ordinary share in USD.

The CEO and chairman bought after negative clinical news. Their combined investment of approximately £7.56 million made the signal significant, while leaving the pipeline, valuation and clinical-trial risks essential to the assessment.

AstraZeneca is a major global pharmaceutical company with exposure to oncology, cardiovascular and renal medicine, respiratory conditions, rare diseases and immunology.

First-half revenue was approximately US$30.7 billion, up 6% at constant currency. Core EPS rose 11%. Guidance called for mid- to high-single-digit revenue growth and low-double-digit Core EPS growth.

Growth increasingly depends on new medicines and expansion of existing franchises. Oncology remains central, while pipeline diversification reduces reliance on any single product.

Trailing P/E was approximately 25x, forward P/E 15–16x and PEG 1.1–1.3.

The forward valuation was considerably more attractive than the trailing multiple, although it depends on forecast earnings being delivered.

Soriot's purchase was unusually large in the context of the supplied assessment. The simultaneous purchase by the chairman strengthened the signal, without establishing the buyers' private motives or guaranteeing future results.

1. Clinical results

New readouts can strengthen the evidence for pipeline candidates, although outcomes are uncertain.

2. Approvals and launches

Approvals can enable commercialisation, while launches can create new revenue.

3. Established franchises

Expanding established medicines can support revenue. A successful pipeline could allow EPS to grow faster than sales.

1. Clinical trials

Negative results can undermine a medicine. The Etcamah failure cited in the research shows that pipeline quality does not eliminate this risk.

2. Patents

Loss of protection can increase competition and pressure revenue.

3. Pricing and regulation

Pricing pressure and regulatory changes can reduce product returns.

At the signal date, the share had recovered from a recent low but was still only a few percentage points above the insiders' purchase prices.

On the London chart, resistance was around 12,500–12,630p, with support at 12,100–12,200p and 11,550–11,700p. RSI near 60–65 indicated positive momentum, rather than oversold conditions, while the share remained below its structural highs.

The share remained well below its 52-week highs, so the recent move did not represent chasing a structural high. The Monthly component of 9.2 reflected this balance between recovery and remaining room.

Monthly reading: recovery below previous highs left structural room, while clinical risk remained present.

AZN · NYSE (USD), London Stock Exchange (GBP; quoted in GBX) and Nasdaq Stockholm (SEK). Since 2 February 2026 NYSE trades AstraZeneca ordinary shares; the former Nasdaq ADS listing ended on 30 January 2026. This research uses the NYSE ordinary share in USD.

The AZN thesis did not require unquestioning belief in the pipeline. Its appeal came from a profitable, diversified global company at an acceptable forward multiple receiving a personal investment of more than £7 million from its CEO immediately after negative news.

That purchase did not remove clinical risk. It made the relationship between known risks, valuation and the reported insider transactions particularly relevant to the assessment.